Cargando…

The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia

The monitoring of the tumor marker cancer antigen 125 (CA-125) is commonly used as a part of epithelial ovarian cancer monitoring for recurrence. This study seeks to calculate the average time between CA-125 elevation above 35 IU/mL and evidence of recurrence through any currently accepted modality...

Descripción completa

Detalles Bibliográficos
Autores principales: Moharrag, Ali, Yonbawi, Faisal, Bashawieh, Hussam H, Basabrain, Ahmed, Al-Jifree, Hatim M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462651/
https://www.ncbi.nlm.nih.gov/pubmed/32884874
http://dx.doi.org/10.7759/cureus.9518
_version_ 1783576962427518976
author Moharrag, Ali
Yonbawi, Faisal
Bashawieh, Hussam H
Basabrain, Ahmed
Al-Jifree, Hatim M
author_facet Moharrag, Ali
Yonbawi, Faisal
Bashawieh, Hussam H
Basabrain, Ahmed
Al-Jifree, Hatim M
author_sort Moharrag, Ali
collection PubMed
description The monitoring of the tumor marker cancer antigen 125 (CA-125) is commonly used as a part of epithelial ovarian cancer monitoring for recurrence. This study seeks to calculate the average time between CA-125 elevation above 35 IU/mL and evidence of recurrence through any currently accepted modality (positive clinical findings, biopsy, imaging, or PET [positron emission tomography] findings) in a patient population in Jeddah, Saudi Arabia. We studied patients who were diagnosed between January 2006 and December 2016, underwent successful primary therapy, and were then followed up at Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia. We adopted a cross-sectional chart review study design. We used inclusive (consecutive) sampling. A total of 13 patients were included, of whom 76.9% (10 patients) developed CA-125 elevations above 35 IU/mL prior to the confirmation of recurrence. If all 13 patients are included in the mean average calculation, the mean average time elapsed between CA-125 elevation and confirmation of recurrence was 161.5 days (standard deviation ± 230.6). If only the 10 patients who did exhibit a CA-125 elevation above 35 IU/mL were included, the mean average was 210 days (standard deviation ± 244.2).
format Online
Article
Text
id pubmed-7462651
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-74626512020-09-02 The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia Moharrag, Ali Yonbawi, Faisal Bashawieh, Hussam H Basabrain, Ahmed Al-Jifree, Hatim M Cureus Obstetrics/Gynecology The monitoring of the tumor marker cancer antigen 125 (CA-125) is commonly used as a part of epithelial ovarian cancer monitoring for recurrence. This study seeks to calculate the average time between CA-125 elevation above 35 IU/mL and evidence of recurrence through any currently accepted modality (positive clinical findings, biopsy, imaging, or PET [positron emission tomography] findings) in a patient population in Jeddah, Saudi Arabia. We studied patients who were diagnosed between January 2006 and December 2016, underwent successful primary therapy, and were then followed up at Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia. We adopted a cross-sectional chart review study design. We used inclusive (consecutive) sampling. A total of 13 patients were included, of whom 76.9% (10 patients) developed CA-125 elevations above 35 IU/mL prior to the confirmation of recurrence. If all 13 patients are included in the mean average calculation, the mean average time elapsed between CA-125 elevation and confirmation of recurrence was 161.5 days (standard deviation ± 230.6). If only the 10 patients who did exhibit a CA-125 elevation above 35 IU/mL were included, the mean average was 210 days (standard deviation ± 244.2). Cureus 2020-08-02 /pmc/articles/PMC7462651/ /pubmed/32884874 http://dx.doi.org/10.7759/cureus.9518 Text en Copyright © 2020, Moharrag et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Obstetrics/Gynecology
Moharrag, Ali
Yonbawi, Faisal
Bashawieh, Hussam H
Basabrain, Ahmed
Al-Jifree, Hatim M
The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia
title The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia
title_full The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia
title_fullStr The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia
title_full_unstemmed The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia
title_short The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia
title_sort average time gap between ca-125 tumor marker elevation and confirmation of recurrence in epithelial ovarian cancer patients at princess noorah oncology center, jeddah, saudi arabia
topic Obstetrics/Gynecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462651/
https://www.ncbi.nlm.nih.gov/pubmed/32884874
http://dx.doi.org/10.7759/cureus.9518
work_keys_str_mv AT moharragali theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT yonbawifaisal theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT bashawiehhussamh theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT basabrainahmed theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT aljifreehatimm theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT moharragali averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT yonbawifaisal averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT bashawiehhussamh averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT basabrainahmed averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia
AT aljifreehatimm averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia